Key Takeaways J&J's Key Competitors in the Medical Devices Market J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic (MDT) , Abbott, Stryker (SYK) and Boston Scientific. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets prod ...

Startup Leo Cancer Care is transforming proton radiation treatment with a simple idea: having patients sit up instead of lying down. Now hospitals that include Stanford and McLaren are lining up to buy dozens of machines. https://t.co/j6wkzeExmH (Photos: Leo Cancer Care) https://t.co/wWyx4zdBPz ...

We are exiting our position in Abbott Laboratories , selling 250 shares at roughly $129. Following the trade, Jim Cramer's Charitable Trust will no longer hold a position in Abbott. Abbott Labs reported a mixed quarter on Wednesday as strength in its medical devices business was partially offset by softness in its nutrition and diagnostics units. For such a high-quality company with a long track record of beating analyst estimates and raising its full-year outlook, this was the second consecutive quarter wh ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

Key Takeaways MMSI's $22M C2 CryoBalloon deal broadens GI portfolio, targeting Barrett's esophagus treatment growth.MMSI expects $6-$8M in 2026 revenues from C2 CryoBalloon, despite near-term EPS dilution through 2025-26.MMSI strengthens GI market presence with innovative ablation tech, enhancing long-term growth outlook.Merit Medical Systems (MMSI) announced that it has signed a definitive agreement to acquire the C2 CryoBalloon technology from Pentax of America, a subsidiary of PENTAX Medical, Inc. The in ...

FAR HILLS, N.J.--(BUSINESS WIRE)-- #AMD--Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®). ...

Key Takeaways Boston Scientific will report third-quarter 2025 results on Oct. 22 before the market opens. Q3 revenues are estimated at $4.97B, up 18.1% year over year, with EPS projected to rise 12.7% to $0.71. TMO's cardiovascular strength, led by WATCHMAN FLX Pro and AGENT DCB, might have boosted performance. Boston Scientific (BSX) is slated to report third-quarter 2025 results on Oct. 22, before market open.The renowned medical device manufacturer posted earnings per share (EPS) of 75 cents in the last ...

THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. As part of the co ...

Good morning. Ulta Beauty, the largest specialty beauty retailer in the U.S., has a new finance chief.Following an external search, the company selected Christopher DelOrefice, who will begin his tenure on Dec. 5; Chris Lialios will continue to serve as interim CFO until then. DelOrefice succeeds former CFO Paula Oyibo, who left the company in June.He joins Ulta Beauty (No. 375 on the Fortune 500) from medical technology company Becton Dickinson & Co., where he has served as EVP and CFO since September 2021 ...

Company Overview - Odyssey Health, Inc. is a medical technology company focused on life-saving medical solutions and aims to create, acquire, and accumulate distinct assets and technologies that provide meaningful medical solutions [6] - Odyssey Medical Devices, Inc. is a wholly owned subsidiary of Odyssey Health, Inc. [6] Product Announcement - Odyssey Health has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a non-invasive test for breast abnormalities [1] - The BreastCheck® test can be performed at home in just 15 minutes, providing immediate results and serving as an effective first-line screening device [2][4] Market Context - The breast cancer diagnostics market is rapidly growing, currently valued in the low tens of billions of dollars, with forecasts to double or more over the next 8-10 years [3] - Early detection has significantly increased breast cancer survival rates, with an estimated 317,000 new cases of invasive breast cancer expected to be diagnosed in women in the U.S. this year [3][5] Technology and Regulatory Status - The technology behind BreastCheck® is FDA registered in the U.S. and also registered with relevant regulatory authorities in the European Union and the United Kingdom [2] - BreastCheck® is designed to be an adjunct to established procedures for breast disease detection, such as clinical breast examinations and mammography [4] Future Outlook - The company expects to begin commercialization and generate initial revenue from BreastCheck® in the near future, marking a transition from a development-stage to a revenue-generating medtech company [3]